Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Stoke Therapeutics (STOK) to $50 from $35 and keeps a Buy rating on the shares. The firm says zorevunersen’s “clinically transformative” 82% seizure reduction and “significant” cognitive gains substantially de-risk the Phase 3 EMPEROR study “which is powered for far more modest improvements.” The analyst received “strong” validation from key opinion leaders supporting its use in severe patients despite safety signals. The new data expande the addressable market to “Atypical Dravet,” the analyst tells investors in a research note.